Browse drugs

…re, limiting its utility. Janus kinase inhibitors, particularly upadacitinib, have shown promise in observational studies, but data remain l…

…ation observed in our JAKi-activated subpopulations.Conclusions Upadacitinib was associated with enhanced platelet activation and procoagula…

… window (>300x based on 14-day non-GLP tox studies).Conclusions LUS012, a highly selective Kv1.3 inhibitor with gut-restricted exposur…

…oral small molecule kinase inhibitors, such as upadacitinib and deucravacitinib, as potential additions to standard of care in SLE, considering…

…Upadacitinib (UPA) is a novel orally administered small molecule drug that w…

…r vaccine (RZV) in patients with rheumatoid arthritis receiving upadacitinib 15 mg once daily (QD) with background methotrexate.Methods Elig…

…is. 48 (71.6%) were commenced on upadacitinib and 19 (28.4%) on filgotinib. 32 (47.8%) patients were initiated on treatment prior to, and …

…citinib or upadacitinib), rituximab, tocilizumab, methotrexate, mycophenolate mofetil, or glucocorticoids (>=10 mg prednisone equivalent daily) for m…

…12 (10–60) 4.5 (0–80) 7.5 (0–10) 0 (0–10) 8.5 (3–10) 3.5 (0–10) Baricitinib 22 (21–40) 1 (0–18) 16 (5–40) 1 (0–10) 6 (0–1) 0 (0–1) 8 (0–5) …

… JAK inhibitors-related AERs extracted from the FAERS database. Baricitinib was associated with an elevated risk of cardiac disorders (ROR=…

…ion of patients achieving SRI-4, BICLA, or LLDAS responses with upadacitinib vs placebo based on changes in MCID for (A) FACIT-fatigue, (B) …

… by fever and fatigue. Two weeks previously he had started oral upadacitinib—a Janus kinase inhibitor—at 15 mg once daily for severe, widesp…